RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $118,627,280 | +41.0% | 15,506,834 | +37.7% | 0.00% | +50.0% |
| Q2 2023 | $84,110,946 | +15.3% | 11,259,832 | +3.0% | 0.00% | 0.0% |
| Q1 2023 | $72,927,005 | -6.0% | 10,933,584 | +8.7% | 0.00% | 0.0% |
| Q4 2022 | $77,542,269 | -13.0% | 10,057,363 | +20.0% | 0.00% | -33.3% |
| Q3 2022 | $89,174,000 | +56.8% | 8,380,986 | +19.9% | 0.00% | +50.0% |
| Q2 2022 | $56,879,000 | +20.2% | 6,987,467 | +5.7% | 0.00% | +100.0% |
| Q1 2022 | $47,338,000 | -54.8% | 6,611,377 | +8.1% | 0.00% | -50.0% |
| Q4 2021 | $104,731,000 | +67.8% | 6,113,873 | +125.4% | 0.00% | 0.0% |
| Q3 2021 | $62,403,000 | -36.3% | 2,711,980 | +1.1% | 0.00% | 0.0% |
| Q2 2021 | $97,934,000 | – | 2,683,107 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |